What is AlgiSys?
Founded in 2009 by Mr. LoPresti and Dr. Roe, AlgiSys operates at the intersection of advanced biological research and industrial application. The company specializes in the commercialization of over a decade of intensive algae research, focusing on high-value applications that address critical needs in nutrition and sustainable resource management. By maintaining a headquarters in Cleveland, Ohio, the firm leverages regional industrial expertise to scale its laboratory-proven methodologies into viable, large-scale production models. AlgiSys distinguishes itself through a deep commitment to scientific rigor, positioning its intellectual property as a cornerstone for future innovations in the biotechnology sector.
How much funding has AlgiSys raised?
AlgiSys has raised a total of $51.4M across 3 funding rounds:
Angel/Seed
$200K
Series A
$6.2M
Series B
$45M
Angel/Seed (2011): $200K, investors not publicly disclosed
Series A (2013): $6.2M, investors not publicly disclosed
Series B (2021): $45M supported by Peakstone Securities
Key Investors in AlgiSys
Peakstone Securities
An investment banking firm providing strategic advisory and capital raising services to middle-market companies across various industrial sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for AlgiSys?
With the successful closure of this major strategic investment, AlgiSys is poised to transition into a phase of aggressive commercial expansion. The company's roadmap likely includes the scaling of production facilities and the strengthening of its supply chain to meet the growing demand for sustainable, algae-derived products. Furthermore, the firm is expected to prioritize the optimization of its proprietary extraction processes to enhance yield and cost-efficiency. As AlgiSys continues to mature, the focus will shift toward securing strategic partnerships and expanding its market footprint, effectively bridging the gap between foundational scientific discovery and global market adoption. The current funding environment provides the necessary runway to navigate these complex operational challenges while maintaining a competitive edge in the rapidly evolving biotech industry.
See full AlgiSys company page
